MA52565B1 - Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-11 immunomodulators - Google Patents

Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-11 immunomodulators

Info

Publication number
MA52565B1
MA52565B1 MA52565A MA52565A MA52565B1 MA 52565 B1 MA52565 B1 MA 52565B1 MA 52565 A MA52565 A MA 52565A MA 52565 A MA52565 A MA 52565A MA 52565 B1 MA52565 B1 MA 52565B1
Authority
MA
Morocco
Prior art keywords
immunomodulators
imidazo
tetrahydro
pyridine derivatives
compounds
Prior art date
Application number
MA52565A
Other languages
French (fr)
Other versions
MA52565A (en
Inventor
Liangxing Wu
Wenqing Yao
Kaijiong Xiao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority claimed from PCT/US2019/031728 external-priority patent/WO2019217821A1/en
Publication of MA52565A publication Critical patent/MA52565A/en
Publication of MA52565B1 publication Critical patent/MA52565B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (i), des procédés d'utilisation des composés en tant qu'immunomodulateurs, et des compositions pharmaceutiques comprenant de tels composés. Les composés sont utiles dans le traitement, la prévention ou l'atténuation de maladies ou de troubles tels que le cancer ou les infections.The invention relates to compounds of formula (i), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in the treatment, prevention or alleviation of diseases or disorders such as cancer or infections.

MA52565A 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-11 immunomodulators MA52565B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670249P 2018-05-11 2018-05-11
PCT/US2019/031728 WO2019217821A1 (en) 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators

Publications (2)

Publication Number Publication Date
MA52565A MA52565A (en) 2021-03-17
MA52565B1 true MA52565B1 (en) 2023-03-31

Family

ID=74446262

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52565A MA52565B1 (en) 2018-05-11 2019-05-10 Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-11 immunomodulators

Country Status (2)

Country Link
AR (1) AR115385A1 (en)
MA (1) MA52565B1 (en)

Also Published As

Publication number Publication date
AR115385A1 (en) 2021-01-13
MA52565A (en) 2021-03-17

Similar Documents

Publication Publication Date Title
MA39783B1 (en) Quinoxaline derivatives useful as modulators of fgfr kinase
MA40111B1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA43979B1 (en) 1h-indazole-3-carboxamide derivatives and similar compounds as d-factor inhibitors for the treatment of diseases characterized by aberrant activity of the complementary system, such as p.E. Immunological disorders
MA41179A (en) PARG INHIBITOR COMPOUNDS
MA40290A1 (en) Immune-regulating agents
TN2014000420A1 (en) INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK
MA47079A (en) AMINO-TRIAZOLOPYIDINE COMPOUNDS AND THEIR USE TO TREAT CANCER
MA31021B1 (en) DERIVATIVES OF ISOQUINOLEINE AND ISOQUINOLEINONE SUBSTITUTED AS RHO-KINASE INHIBITORS
MA53399B1 (en) Substituted pyrazoles as inhibitors of human plasma kallikrein
MA45153B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MA40123A1 (en) Pyrimidines used as factor xia inhibitors
MA38483A1 (en) Inhibitors of ido
MA31022B1 (en) SUBSTITUTED ISOQUINOLINE AND ISOQUINOLEINONE DERIVATIVES
MA40768A (en) MONO OR DI-SUBSTITUTE INDOLE DERIVATIVES AS DENGUE VIRUS REPLICATION INHIBITORS
MA38391B1 (en) Pyridinyl and triazolone pyridinyl derivatives of fusion
MA40769B1 (en) Mono- or di-substituted isolates used as replication inhibitors of dengue virus
MA30539B1 (en) PIPERAZINYL DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES INDUCED BY THE GPR38 RECEPTOR.
MA34545B1 (en) CO-CRYSTALS AND SALTS OF CCR3 INHIBITORS
MA46229B1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MA40149A1 (en) Substituted 4'-vinyl nucleoside derivatives useful as inhibitors of respiratory syncytial virus rna replication
MA44965A (en) PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES OF THEM AS AOC3 INHIBITORS
MA39253B1 (en) Substituted bicyclic heteroaryl compounds used as rxr agonists
MA53372B1 (en) Pyridopyrimidinenes as histamine h4 receptor inhibitors
MA52565B1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-11 immunomodulators
MA52220B1 (en) Heterocyclic compounds used as immunomodulators